GlassScriptPhysician profile
Howard Liu
NPI 1982668026
$45,578.46
in general payments reported to CMS, 2019-2025
26 companies · $2,617 in 2025
The $2,617 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,722 · 2020: $561 · 2021: $3,178 · 2022: $1,613 · 2023: $29K · 2024: $1,833 · 2025: $2,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $6,184 · Travel and Lodging: $109 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,205.93 |
| Food and Beverage | $6,183.70 |
| Travel and Lodging | $108.98 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,536.12 | 2020-2025 | |
| Allergan, INC. | $10,048.49 | 2019-2022 | |
| Galderma Laboratories, L.P. | $9,296.80 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $1,153.80 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,147.62 | 2021-2025 | |
| Incyte Corporation | $1,023.34 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $597.79 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $395.27 | 2019-2025 | Winlevi |
| Ucb, INC. | $368.70 | 2025 | Bimzelx |
| Amgen INC. | $330.37 | 2024-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $231.47 | 2022-2025 | Tremfya |
| Pfizer INC. | $227.64 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $221.97 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $187.82 | 2022-2025 | |
| Dermavant Sciences, INC. | $138.91 | 2023-2024 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $119.15 | 2021-2024 | Adbry |
| Almirall LLC | $117.31 | 2022-2025 | Seysara, Klisyri |
| Botanix Sb INC | $112.22 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.48 | 2023-2024 | Cyltezo |
| Kyowa Kirin, INC. | $81.96 | 2022-2023 | Poteligeo |
| Verrica Pharmaceuticals INC. | $32.87 | 2023 | Ycanth |
| Merz North America, INC. | $31.57 | 2021 | |
| Organon LLC | $28.20 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.77 | 2022 | |
| Sebela Pharmaceuticals INC. | $17.57 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $17.25 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.